Inhibiting mutant IDH-1
Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
1. A method of treating a patient diagnosed with a relapsed or refractory glioma having a R132H IDH1 mutation, the method comprising orally administering to the patient in need thereof a pharmaceutical composition comprising 150 mg of a compound of Formula (1) twice per day (BID):
in an oral unit dosage form, on consecutive days throughout a course of treatment of at least 15 consecutive days.
2. The method of claim 1 , wherein the patient is diagnosed with histologically or cytologically confirmed IDH1 gene-mutated advanced glioma or glioblastoma multiforme with confirmed IDH1 gene-mutated disease with first or second recurrence, prior to the administration of the compound of Formula (1).
3. The method of claim 1 , wherein the compound of Formula (1) is administered to the patient as a single agent for the treatment of the glioma.